Evidence map›Paper›PMID 33856546›Full record

ArticleJournal of neurology2021

High prevalence of serum anti-NH

Akio Kikuchi, Makoto Yoneda, Takafumi Hasegawa, Akiko Matsunaga, Masamichi Ikawa, Takaaki Nakamura, Michinori Ezura, Toru Baba, Naoto Sugeno, Shun Ishiyama and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Akio Kikuchi *Department of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. akikuchi@med.tohoku.ac.jp.ORCID http://orcid.org/0000-0002-9246-6347
Makoto Yoneda *Faculty of Nursing and Social Welfare Sciences, Fukui Prefectural University, 4-1-1 Kenjojima, Matsuoka, Eiheiji, Fukui, 910-1195, Japan. myoneda@fpu.ac.jp.
Takafumi HasegawaDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Akiko MatsunagaSecond Department of Internal Medicine, University of Fukui, Fukui, Japan.
Masamichi IkawaSecond Department of Internal Medicine, University of Fukui, Fukui, Japan.
Takaaki NakamuraDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Michinori EzuraDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Toru BabaDepartment of Neurology, National Hospital Organization, Sendai Nishitaga Hospital, Sendai, Japan.
Naoto SugenoDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Shun IshiyamaDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Yasunari NakamotoSecond Department of Internal Medicine, University of Fukui, Fukui, Japan.
Atsushi TakedaDepartment of Neurology, National Hospital Organization, Sendai Nishitaga Hospital, Sendai, Japan.
Masashi AokiDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Tohoku University · JPUniversity of Fukui · JPSendai Nishitaga National Hospital · JPFukui Prefectural University · JP

Funding

Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (C) (20K07923)
6 · The paper itself

Abstract

backgroundHashimoto's encephalopathy with serum anti-NH

methodsWe examined the positive rates of anti-NAE antibodies in 47 patients with multiple system atrophy (MSA), 29 patients with Parkinson's disease (PD), eight patients with corticobasal syndrome (CBS), and 18 patients with progressive supranuclear palsy (PSP) using conventional immunoblot analysis.

resultsPositive anti-NAE antibody rates of 31.9%, 10.3%, 50.0%, and 11.1% were reported in the MSA, PD, CBS, and PSP patients, respectively. The duration from onset to a wheelchair-bound state in seropositive MSA patients tended to be shorter than that in seronegative MSA patients.

conclusionsAnti-NAE antibodies are detected in some patients clinically diagnosed with MSA and CBS. Although its pathophysiological significance remains uncertain, serum anti-NAE antibodies might represent a prognostic marker in the clinical course of MSA.

Indexed as

Multiple System AtrophyParkinson DiseaseSupranuclear Palsy, ProgressiveHumansPhosphopyruvate HydratasePrevalencePhosphopyruvate HydrataseAnti-NH2-terminal of α-enolase antibodiesCorticobasal syndromeMultiple system atrophyParkinson’s diseaseProgressive supranuclear palsy

Identifiers

PMID33856546
OpenAlexW3154254643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.